Literature DB >> 3360049

Serum doxapram and respiratory neuromuscular drive in normal man.

S Okubo1, K Konno, T Ishizaki, T Suganuma, T Takubo, T Takizawa, M Tanaka.   

Abstract

To investigate the means by which doxapram affects the control of ventilation, ventilatory function and P0.1 have been related to serum doxapram concentration during a 45-min infusion of doxapram hydrochloride in 7 healthy, conscious subjects under normoxic conditions. Serum doxapram concentrations increased during the infusion: 1.88, 2.48, 3.42, and 3.97 micrograms/ml after 5, 10, 30 and 45 min, respectively. The majority of significant changes in the measurements from the baseline were observed at 30 and 45 min: VE, VT, P0.1, P0.1/end-tidal CO2 tension, VT/Ti and blood pressure were increased, and end-tidal CO2 tension was decreased. No significant changes in Pdimax, Ti/Ttot, VE/P0.1, and P0.1/(VT/Ti) were observed. A correlation was observed between the % increases in P0.1 and VE and doxapram concentration, and between VE and P0.1. The doxapram-induced increase in VE appears to be caused by increased neural drive. It is related to the serum drug concentration in the conscious subject.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3360049     DOI: 10.1007/bf01061418

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Rapid gas--liquid chromatographic estimation of doxapram in plasma.

Authors:  R H Robson; L F Prescott
Journal:  J Chromatogr       Date:  1977-09-01

2.  Drive and timing components of ventilation.

Authors:  J Milic-Emili; M M Grunstein
Journal:  Chest       Date:  1976-07       Impact factor: 9.410

3.  Evidence of a role for the peripheral chemoreceptors in the ventilatory response to doxapram in man.

Authors:  R M Scott; J G Whitwam; M K Chakrabarti
Journal:  Br J Anaesth       Date:  1977-03       Impact factor: 9.166

4.  Physiologic effects of doxapram in idiopathic apnea of prematurity.

Authors:  K J Barrington; N N Finer; K L Peters; J Barton
Journal:  J Pediatr       Date:  1986-01       Impact factor: 4.406

5.  Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentrations.

Authors:  F Hayakawa; S Hakamada; K Kuno; T Nakashima; Y Miyachi
Journal:  J Pediatr       Date:  1986-07       Impact factor: 4.406

6.  Measurement of the separate volume changes of rib cage and abdomen during breathing.

Authors:  K Konno; J Mead
Journal:  J Appl Physiol       Date:  1967-03       Impact factor: 3.531

7.  A pharmacokinetic study of doxapram in patients and volunteers.

Authors:  R H Robson; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

8.  Ventilatory effects of doxapram in conscious human subjects.

Authors:  N K Burki
Journal:  Chest       Date:  1984-05       Impact factor: 9.410

9.  Interaction of baroreceptor and chemoreceptor reflexes. Modulation of the chemoreceptor reflex by changes in baroreceptor activity.

Authors:  D D Heistad; F M Abboud; A L Mark; P G Schmid
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

10.  The disposition of intravenous doxapram in man.

Authors:  J A Clements; R H Robson; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.